Genitourinary tumour therapy developer Asieris Pharmaceuticals has closed a Series D round of financing raising over 700 million yuan ($106 million) led by Chinese global venture capital firm Qiming Venture Partners, according to a company statement on Wednesday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
